Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers
2023-507600-32-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing PCV21 with Vaxneuvance (2 arms). Planned start May 2025; status: authorised.
02
Drugs
SP0202pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2023-507600-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507600-32-00.